**Contributors and Co-investigators**

**ONWARD (Oral cladribine added oN to interferon β in patients With Active Relapsing Disease) trial investigators, by country, were:**

**Italy**: Giancarlo Comi, MD (Università Vita-Salute San Raffaele, Ospedale San Raffaele Milano, Site Investigator); Paolo Gallo, MD, PhD (Universita Degli Studi di Padova Clinica Neurologica Azienda Ospedaliera Padova, Site Investigator); Carlo Pozzilli, MD (Universita di Roma La Sapienza, Site Investigator); Claudio Gasperini, MD, PhD (Azienda Ospedaliera San Camillo-Forlanini Roma, Site Investigator); Vincenzo Brescia Morra, MD (Federico II Hospital Naples, Site Investigator).

**Russia:** Alexey N Boyko, MD, PhD (Pirogov Russian National Research Medical University Moscow, Site Investigator); Olga Amelina, MD, PhD (International Clinic and Hospital St Petersburg, Site Investigator); Sergey V Kotov, MD (Moscow Regional Research and Clinical Institute, Site Investigator); Lilia Novikova, MD, PhD (Bashkir State Medical University Ufa, Site Investigator); Olga Patrusheva (North State Medical University, Department of Psychiatry, Arkhangelsk, Site Investigator); Igor Zavalishin, MD, DMedSc (Research Institute of Neurology Moscow, Site Investigator); Farid Khabirov, MD, PhD (APHCI Republican Clinical Hospital of Medical Rehabilitation Kazan, Site Investigator); Natalia Maslova, MD, PhD (OGUZ Smolensk Regional Clinical Hospital, Smolensk, Site Investigator); Nadezda Malkova, MD (Novosibirsk Regional Center of MS, Novosibirsk Site Investigator); Irina E Poverennova, MD, PhD, DMS (Samara State Medical University, State Educational Institution of Higher Professional Education, Site Investigator).

**Spain:** Xavier Montalban, MD, PhD (Universitario Vall d'Hebron, Multiple Sclerosis Centre of Catalonia Barcelona, Coordinating and Principal Investigator); Sergio Martinez Yelamos, MD (University Hospital Bellvitge, Department of Clinical Sciences of the Faculty of Medicine of the University of Barcelona, Site Investigator); Guillermo Izquierdo, MD, PhD (Virgen de la Macarena Seville, Site Investigator); Oscar Fernandez, MD, PhD (Instituto de Investigación Biomédica de Málaga (IBIMA), Site Investigator); Alfredo Rodriguez-Antiguedad, MD (Hospital de Basurto Bilbao, Site Investigator); Angel Perez Sempere, MD (Hospital Universitario General de Alicante, Site Investigator); Rafael Arroyo, MD (Quirónsalud University Hospital Madrid, Quirón San Camilo Hospital Madrid, Site Investigator); Bonaventura Casanova, MD (Joint Research Unit in Multiple Sclerosis and Neuroregeneration, Hospital Universitario Sanitaria La Fe Valencia, Site Investigator); Manual Arias, MD (Complejo Hospitalario Universitario de Santiago, Site Investigator).

**USA:** Mark Cascione, MD (South Tampa Multiple Sclerosis Center, Tampa Neurology Associates, Tampa Florida, Site Investigator); Bruce Arnold Cohen, MD (Northwestern University, Chicago, Illinois, Principal Investigator); Edward Fox, MD, PhD (MS Clinic of Central Texas, Round Rock, Texas, Site Investigator); Regina Berkovich, MD, PhD (Keck Hospital of USC, Los Angeles California, Site Investigator); Michael Kaufman, MD (Carolinas Medical Center, Charlotte, North Carolina, Site Investigator); Thomas Leist, MD, PhD (Division of Clinical Neuroimmunology Comprehensive MS Center, Thomas Jefferson University, Philadelphia Pennsylvania, Principal Investigator); Dina Jacobs, MD (Hospital of the University of Pennsylvania, Philadelphia, Site Investigator); Tamara Miller, MD (Poudre Valley Hospital, Medical Center of the Rockies, and UC Health Memorial, Fort Collins, Colorado, Site Investigator); Harold Moses, MD (Neuroimmunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville Tennessee, Principal Investigator); Michael Racke, MD (Ohio State University School of Medicine, Columbus Ohio, Site Investigator); George Hutton, MD (Maxine Mesinger MS Comprehensive Care Center, Baylor College of Medicine, Houston Texas, Site Investigator); Barry Singer, MD (Missouri Baptist Medical Center St Louis Missouri, Site Investigator); Kiren Kresa-Reahl, MD (Providence MS Center, Portland Oregon, Site Investigator); Emily Pharr, MD (Wake Forest University Health Sciences, Winston-Salem North Carolina, Site Investigator); Jonathan L Carter, MD (Mayo Clinic Scottsdale Arizona, Site Investigator); Jeanette Wendt, MD (Northwest NeuroSpecialists PLLC, Tucson Arizona, Site Investigator); Rup Tandan, MD, FRCP (University of Vermont VHC Campus, Burlington Vermont, Site Investigator); Roberto Bomprezzi, MD, PhD (Barrow Neurological Institute, St Joseph Medical Center, Phoenix, Arizona, Site Investigator); Corey Ford, MD, PhD, FAAN (University of New Mexico Health Science Center, Clinical and Magnetic Resonance Research Center, Albuquerque New Mexico, Site Investigator); Stephen Kamin, MD (University of Medicine and Dentistry of New Jersey, Newark, Site Investigator); Misha Pless, MD (Massachusetts General Hospital, Boston, Site Investigator); George P Garmany, MD (Alpine Clinical Research Center, Boulder Colorado, Site Investigator); Suzanne Gazda, MD (Neurology Institute of San Antonio Texas, Site Investigator); Jeffrey English, MD (MS Center of Atlanta, Piedmont Atlanta Hospital, Georgia, Site Investigator); Barbara Green, MD (Saint John’s Mercy Medical Center, St Louis, Missouri, Site Investigator); Dennis Garwacki, MD (OSF Saint Francis Medical Center, Peoria Illinois, Site Investigator); Jeffrey Gould, MD (Diplomate of American Board of Sleep Medicine, P.C. Bethlehem Pennsylvania, Site Investigator); Chris LaGanke, MD (Central Neurology Associates, Cullman Alabama, Site Investigator).